Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
February 21, 2024 07:30 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling...
Absci to Participate in Upcoming Investor Conferences
February 20, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
January 10, 2024 07:30 ET
|
Absci Corporation
Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific...
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 07:00 ET
|
Absci Corporation
Preclinical data support profile for development of a potential best-in-class drug IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash....
Absci to Participate in the 26th Annual Needham Growth Conference
January 03, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually...
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
December 20, 2023 07:30 ET
|
Absci Corporation
Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten...
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
December 04, 2023 07:30 ET
|
Absci Corporation
VANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global...
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 15, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
November 14, 2023 16:05 ET
|
Absci Corporation
Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties Unveiled AI drug creation pipeline of four...